Treatment selection in castration-resistant prostate cancer

Expert: Giulia Baciarello, National Cancer Institute - IRCCS Foundation, Milan, Italy Questions: 1-Is there a specific patient group in which you prefer using chemotherapy instead of androgen receptor pathway inhibitors? 2-Are there any clinical factors aiding the selection between abiraterone and enzalutamide? 3-Should we refrain from abiraterone treatment in patients with diabetes? 4-What should be the optimal treatment line for Lu-177 PSMA treatment in castration-resistant prostate cancer? 5-Is there a role of immunotherapy in castration-resistant prostate cancer in current clinical practice?